報價延遲最少15分鐘:2026/06/11 05:16 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.41
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-142.72/-12.43
|
|
企業價值
17.01M
|
| 資產負債 |
|
每股賬面淨值
-102.30
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Sensei Biotherapeutics Inc is a clinical-stage biotechnology company engaged in the development of therapies targeting cancer through multi-node inhibition of oncogenic pathways. The company's lead program, PIKTOR, is an investigational oral combination therapy designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway and is being evaluated for the treatment of endometrial and breast cancers. In addition, the company is advancing other pipeline programs targeting tumormetabolism and signaling pathways. |
